2.81
0.12 (4.46%)
| Penutupan Terdahulu | 2.69 |
| Buka | 2.70 |
| Jumlah Dagangan | 3,124,382 |
| Purata Dagangan (3B) | 2,001,798 |
| Modal Pasaran | 945,753,280 |
| Harga / Jualan (P/S) | 297.57 |
| Harga / Buku (P/B) | 1.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -6,616.37% |
| EPS Cair (TTM) | -2.18 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.23% |
| Nisbah Semasa (MRQ) | 9.57 |
| Aliran Tunai Operasi (OCF TTM) | -99.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -33.29 M |
| Pulangan Atas Aset (ROA TTM) | -13.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -95.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Nuvation Bio Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 26.85% |
| % Dimiliki oleh Institusi | 56.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2024 | 25,954,439 |
| Ecor1 Capital, Llc | 30 Sep 2024 | 19,209,643 |
| Omega Fund Management, Llc | 30 Sep 2024 | 13,072,340 |
| Octagon Capital Advisors Lp | 30 Sep 2024 | 12,171,513 |
| Tang Capital Management Llc | 30 Sep 2024 | 3,900,000 |
| Aisling Capital Management Lp | 30 Sep 2024 | 2,541,009 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (RBC Capital, 113.52%) | Beli |
| Median | 5.50 (95.73%) | |
| Rendah | 5.00 (Wedbush, 77.94%) | Beli |
| Purata | 5.50 (95.73%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 07 Nov 2024 | 6.00 (113.52%) | Beli | 2.62 |
| Wedbush | 22 Oct 2024 | 5.00 (77.94%) | Beli | 2.41 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Dec 2024 | Pengumuman | Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration |
| 26 Nov 2024 | Pengumuman | Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference |
| 12 Nov 2024 | Pengumuman | Nuvation Bio to Present at the Jefferies London Healthcare Conference |
| 06 Nov 2024 | Pengumuman | Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 07 Oct 2024 | Pengumuman | Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |